Edition: United Kingdom  
One News Page
“Probably the fastest-access news portal in the world”
> >

Naia Rare Diseases Announces Clinical Trial Authorisation (CTA) to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom

Marketwired Wednesday, 15 November 2017 ()
RICHMOND, CA--(Marketwired - November 15, 2017) - Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases today announced that it has received Clinical Trial Authorisation ("CTA") from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

You Might Like


Other recent news in Press Releases

Fly the Happiest and Safest Skies THANKSGIVING WeekendChina’s DHgate Launches Digital Trade Center (DTC) in California, Texas, and FLORIDA
Encore Consumer Capital Announces Sale of Atlantic Aqua Farms to ONTARIO Teachers’A.M. Best Maintains Under Review With Developing Implications Status for Credit Ratings of Macau LIFE INSURANCE Company Limited
NINJA BLENDER - SOLLUME ESTHÉ Distributor G&J Completes Venture Company Certification by Ministry of SMEs and Startups (MSS) in SOUTH KOREALincoln Financial Group’s Carrie Chelko Receives 2017 Women of Distinction Award from PHILADELPHIA Business Journal
Pampers Helped Celebrate the #LittlestFighters at Connecticut Children’s Medical Center In Honor of WORLD PREMATURITY DAY3M™ Tegaderm™ CHG I.V. Securement Dressing Only TRANSPARENT Dressing to Meet New CDC Recommendation for Reducing Catheter-Related Bloodstream Infections
Alternative Rock Radio Returns to NEW YORK CITY with the Launch of ALT 92.3 FMCharter SENIOR LIVING Hires Sallerson as Chief Sales & Strategy Officer

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+